Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center-Reference-Cited by-同舟云学术

Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center

Published:2019 Issue:7/8 Volume:42 Page:396-404
ISSN:2296-5270
Container-title:Oncology Research and Treatment
language:en
Short-container-title:Oncol Res Treat

Author:

Langmans Ciska,Cornillie Jasmien,van Cann Thomas,Wozniak Agnieszka,Hompes Daphne,Sciot Raf,Debiec-Rychter Maria,Vandenbempt Isabelle,Schöffski Patrick

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. Corey RM, Swett K, Ward WG. Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med. 2014 Oct;3(5):1404–15.

2. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer. 2006 Dec;119(12):2922–30.

3. Mastrangelo G, Coindre JM, Ducimetière F, Dei Tos AP, Fadda E, Blay JY, et al. Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. Cancer. 2012 Nov;118(21):5339–48.

4. Crago AM, Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol. 2011 Jul;23(4):373–8.

5. Rieker RJ, Weitz J, Lehner B, Egerer G, Mueller A, Kasper B, et al. Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways. Virchows Arch. 2010 Mar;456(3):277–85.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors;ESMO Open;2024-08

2. Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report;ESMO Open;2024-07

3. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms;Cancer Treatment Reviews;2024-04

4. The Predictive Role of the Histopathological Scoring System in Adipose Tumors—Lipoma, Atypical Lipomatous Tumor, and Liposarcoma;Diagnostics;2023-12-05

5. Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS;Future Oncology;2023-03